Prothrombin Time and Partial Thromboplastin Time Assay Considerations

Clinics in Laboratory Medicine

Volumn 29, Issue 2, 2009, Pages 253-263

  Ng, Valerie L ^a  

^a HIGHLAND HOSPITAL   (United States)

Author keywords

FVIII; International normalized ratio; Partial thromboplastin; Partial thromboplastin time; Prothrombin time; Reagent; Standardization; Thromboplastin

Indexed keywords

ANTIVITAMIN K; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; PROTHROMBIN; REAGENT; THROMBOPLASTIN; WARFARIN;

ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TEST; CLINICAL PRACTICE; HUMAN; HYPERCOAGULABILITY; INFORMATION PROCESSING; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RELIABILITY; REPRODUCIBILITY; SENSITIVITY ANALYSIS; SPECTROPHOTOMETRY; STANDARDIZATION;

FACTOR VIII; HUMANS; INTERNATIONAL NORMALIZED RATIO; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME;

EID: 68149137642     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2009.05.002     Document Type: Article

References (55)

1. Biggs R., and Macfarlane R. Estimation of prothrombin in dicoumarin therapy. J Clin Pathol 2 (1949) 33-44
2. Massignon D., Moulsma M., Bondon P., et al. Prothrombin time sensitivity and specificity to mild clotting factor deficiencies of the extrinsic pathway: evaluation of eight commercial thromboplastins. Thromb Haemost 75 4 (1996) 590-594
3. Poggio M., van den Besselaar A.M., van der Velde E.A., et al. The effect of some instruments for prothrombin time testing on the International Sensitivity Index (ISI) of two rabbit tissue thromboplastin reagents. Thromb Haemost 62 3 (1989) 868-874
4. Thomson J.M., Taberner D.A., and Poller L. Automation and prothrombin time: a United Kingdom field study of two widely used coagulometers. J Clin Pathol 43 8 (1990) 679-684
5. Triplett D.A., Brandt J.T., Batard M.A., et al. Hereditary factor VII deficiency: heterogeneity defined by combined functional and immunochemical analysis. Blood 66 6 (1985) 1284-1287
6. Pollak E.S., Russell T.T., Ptashkin B., et al. Asymptomatic factor VII deficiency in African Americans. Am J Clin Pathol 126 1 (2006) 128-132
7. Worfolk L. Thromboplastin correlation study. Available at:. http://ekomed-diagnostic.com/pacific_hemostasis/PacifichemostasisPTkorrelasyonraporu.pdf Accessed January 24, 2009
8. Poller L. Standardization of anticoagulant control. Ric Clin Lab 8 4 (1978) 237-247
9. Poller L. International Normalized Ratios (INR): the first 20 years. J Thromb Haemost 2 6 (2004) 849-860
10. Poller L., Keown M., Chauhan N., et al. European concerted action on anticoagulation. Use of plasma samples to derive International Sensitivity Index for whole-blood prothrombin time monitors. Clin Chem 48 2 (2002) 255-260
11. Thomson J.M., Darby K.V., and Poller L. Calibration of BCT/441, the ICSH reference preparation for thromboplastin. Thromb Haemost 55 3 (1986) 379-382
12. van den Besselaar A.M. Standardization of the prothrombin time in oral anticoagulant control. Haemostasis 15 4 (1985) 271-277
13. Hull R., Hirsh J., Jay R., et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 307 27 (1982) 1676-1681
14. Kirkwood T.B. Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb Haemost 49 3 (1983) 238-244
15. Favaloro E.J., and Adcock D.M. Standardization of the INR: how good is your laboratory's INR and can it be improved?. Semin Thromb Hemost 34 7 (2008) 593-603
16. Fiebig E.W., Etzell J.E., and Ng V.L. Clinically relevant differences in prothrombin time and INR values related to blood sample collection in plastic vs glass tubes. Am J Clin Pathol 124 6 (2005) 902-909
17. Thomson J.M., Tomenson J.A., and Poller L. The calibration of the second primary international reference preparation for thromboplastin (thromboplastin, human, plain, coded BCT/253). Thromb Haemost 52 3 (1984) 336-342
18. WHO. WHO Expert Committee on biological standardization guidelines for thromboplastins and plasma used to control oral anticoagulant therapy (1999), WHO, Geneva
19. Ng V.L., Levin J., Corash L., et al. Failure of the International Normalized Ratio to generate consistent results within a local medical community. Am J Clin Pathol 99 6 (1993) 689-694
20. Ts'ao C., and Neofotistos D. The use and limitations of the INR system. Am J Hematol 47 1 (1994) 21-26
21. Talstad I. Why is the standardization of prothrombin time a problem?. Haemostasis 30 5 (2000) 258-267
22. Ng V.L., Valdes-Camin R., Gottfried E.L., et al. Highly sensitive thromboplastins do not improve INR precision. Am J Clin Pathol 109 3 (1998) 338-346
23. Smith S.A., and Morrissey J.H. Properties of recombinant human thromboplastin that determine the International Sensitivity Index (ISI). J Thromb Haemost 2 9 (2004) 1610-1616
24. Smith S.A., Comp P.C., and Morrissey J.H. Phospholipid composition controls thromboplastin sensitivity to individual clotting factors. J Thromb Haemost 4 4 (2006) 820-827
25. Adcock D., Brien W., Duff S., et al. Procedures for validation of INR and local calibration of PT/INR systems; approved guideline (2005), Clinical and Laboratory Standards Institute, Wayne (PA) p. H54-A
26. Arkin C. Do we need the geometric mean as the mean normal value in INR determination?. J Thromb Haemost 3 Suppl 1 (2005) [abstract number: P1903]
27. van den Besselaar A.M., Neuteboom J., Meeuwisse-Braun J., et al. Preparation of lyophilized partial thromboplastin time reagent composed of synthetic phospholipids: usefulness for monitoring heparin therapy. Clin Chem 43 7 (1997) 1215-1222
28. Leichsenring I., Plesch W., Unkrig V., et al. Multicentre ISI assignment and calibration of the INR measuring range of a new point-of-care system designed for home monitoring of oral anticoagulation therapy. Thromb Haemost 97 5 (2007) 856-861
29. Critchfield G.C., Bennett S.T., and Swaim W.R. Calibration verification of the International Normalized Ratio. Am J Clin Pathol 106 6 (1996) 786-794
30. Chantarangkul V., Frontoni R., Gresele P., et al. Usefulness of lyophilized calibration plasmas for International Normalized Ratio determination with the bovine combined thromboplastin (thrombotest): results of a collaborative study. Blood Coagul Fibrinolysis 16 2 (2005) 157-163
31. Favaloro E.J., Hamdam S., McDonald J., et al. Time to think outside the box? Prothrombin time, international normalised ratio, International Sensitivity Index, mean normal prothrombin time and measurement of uncertainty: a novel approach to standardisation. Pathology 40 3 (2008) 277-287
32. McKernan A., Thomson J.M., and Poller L. The reliability of international normalized ratios during short-term oral anticoagulant treatment. Clin Lab Haematol 10 1 (1988) 63-71
33. Bellest L., Eschwege V., Poupon R., et al. A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology. Hepatology 46 2 (2007) 528-534
34. Robert A., and Chazouilleres O. Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio?. Hepatology 24 6 (1996) 1392-1394
35. Kovacs M.J., Wong A., MacKinnon K., et al. Assessment of the validity of the INR system for patients with liver impairment. Thromb Haemost 71 6 (1994) 727-730
36. Deitcher S.R. Interpretation of the international normalised ratio in patients with liver disease. Lancet 359 9300 (2002) 47-48
37. Dufour D.R., Lott J.A., Nolte F.S., et al. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin Chem 46 12 (2000) 2027-2049
38. Cholongitas E., Papatheodoridis G.V., Vangeli M., et al. Systematic review: the model for end-stage liver disease-should it replace Child-Pugh's classification for assessing prognosis in cirrhosis?. Aliment Pharmacol Ther 22 11-12 (2005) 1079-1089
39. Reddy N.M., Hall S.W., and MacKintosh F.R. Partial thromboplastin time: prediction of adverse events and poor prognosis by low abnormal values. Arch Intern Med 159 22 (1999) 2706-2710
40. Tripodi A., and Mannucci P.M. Activated partial thromboplastin time (APTT). New indications for an old test?. J Thromb Haemost 4 4 (2006) 750-751
41. Bobrow R.S. Excess factor VIII: a common cause of hypercoagulability. J Am Board Fam Pract 18 2 (2005) 147-149
42. Sauls D.L., Banini A.E., Boyd L.C., et al. Elevated prothrombin level and shortened clotting times in subjects with type 2 diabetes. J Thromb Haemost 5 3 (2007) 638-639
43. Tripodi A., Chantarangkul V., Martinelli I., et al. A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood 104 12 (2004) 3631-3634
44. Brandt J.T., and Triplett D.A. Laboratory monitoring of heparin. Effect of reagents and instruments on the activated partial thromboplastin time. Am J Clin Pathol 76 Suppl 4 (1981) 530-537
45. D'Angelo A., Seveso M.P., D'Angelo S.V., et al. Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT). Implications in heparin monitoring by APTT. Am J Clin Pathol 94 3 (1990) 297-306
46. Kitchen S., Jennings I., Woods T.A., et al. Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage. J Clin Pathol 49 1 (1996) 10-14
47. Brandt J.T., Arkin C.F., Bovill E.G., et al. Evaluation of APTT reagent sensitivity to factor IX and factor IX assay performance. Results from the College of American Pathologists Survey Program. Arch Pathol Lab Med 114 2 (1990) 135-141
48. Hales S.C., Johnson G.S., and Wagner D. Comparison of six activated partial thromboplastin time reagents: intrinsic system factors' sensitivity and responsiveness. Clin Lab Sci 3 3 (1990) 194-196
49. Sahud M. Coagulation tests in differential diagnosis. Clin Lab Haematol 22 Suppl 1 (2000) 2-8 [discussion: 30-2]
50. Burns E.R., Goldberg S.N., and Wenz B. Paradoxic effect of multiple mild coagulation factor deficiencies on the prothrombin time and activated partial thromboplastin time. Am J Clin Pathol 100 2 (1993) 94-98
51. Korte W., Clarke S., and Lefkowitz J.B. Short activated partial thromboplastin times are related to increased thrombin generation and an increased risk for thromboembolism. Am J Clin Pathol 113 1 (2000) 123-127
52. Hron G., Eichinger S., Weltermann A., et al. Prediction of recurrent venous thromboembolism by the activated partial thromboplastin time. J Thromb Haemost 4 4 (2006) 752-756
53. Ten Boekel E., and Bartels P. Abnormally short activated partial thromboplastin times are related to elevated plasma levels of TAT, F1+2, D-dimer and FVIII: C. Pathophysiol Haemost Thromb 32 3 (2002) 137-142
54. Bick R.L. Disseminated intravascular coagulation current concepts of etiology, pathophysiology, diagnosis, and treatment. Hematol Oncol Clin North Am 17 1 (2003) 149-176
55. Ten Boekel E., Bock M., Vrielink G.J., et al. Detection of shortened activated partial thromboplastin times: an evaluation of different commercial reagents. Thromb Res 121 3 (2007) 361-367